Clinical, quality of life, and economic value of acromegaly disease control
Open Access
- 20 May 2011
- journal article
- review article
- Published by Springer Science and Business Media LLC in Pituitary
- Vol. 14 (3), 284-294
- https://doi.org/10.1007/s11102-011-0310-7
Abstract
No abstract availableKeywords
This publication has 71 references indexed in Scilit:
- AcromegalyBMJ, 2010
- Medical Therapy of AcromegalyDrugs, 2009
- Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the diseaseActa Endocrinologica, 2008
- Results of surgical and somatostatin analog therapies and their combination in acromegaly: a retrospective analysis of the German Acromegaly RegisterActa Endocrinologica, 2008
- Somatostatin agonists for treatment of acromegalyMolecular and Cellular Endocrinology, 2008
- Excess Mortality in AcromegalyHormone Research in Paediatrics, 2007
- AcroBel – the Belgian registry on acromegaly: a survey of the ‘real-life’ outcome in 418 acromegalic subjectsActa Endocrinologica, 2007
- Health-related quality of life in acromegalic subjects: data from AcroBel, the Belgian Registry on acromegalyActa Endocrinologica, 2007
- LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapyAtherosclerosis, 2000
- Transsphenoidal Microsurgery for Growth Hormone-Secreting Pituitary Adenomas: Initial Outcome and Long-Term ResultsJournal of Clinical Endocrinology & Metabolism, 1998